Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Sep 2016
At a glance
- Drugs Fresolimumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SABR-ATAC
- 26 Sep 2016 Planned primary completion date changed from 1 May 2019 to 1 Jan 2020.
- 13 Sep 2016 Status changed from not yet recruiting to recruiting.
- 26 Oct 2015 New trial record